parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in neutrophils	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 6	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 9480

TCP11L2 in dopamine neurons, braak-0.19 (p 0.631) → +0.00 (p 1.000)receipt 9487
TCP11L2 in oligodendrocytes, braak-0.30 (p 0.428) → -0.21 (p 0.584)receipt 9486

receipt 9487: TCP11L2 in dopamine neurons, braak

power: full sample -0.21 (p 0.393, n 18), 95% CI -0.62 to +0.28. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.18 (p 0.476, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.17 (p 0.498, n 18). could be the mix.
skeptic: leave-one-out range -0.35 to -0.14, sign flips 0; without severely affected donors -0.21 (p 0.393, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TCP11L2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 9486: TCP11L2 in oligodendrocytes, braak

power: full sample -0.33 (p 0.182, n 18), 95% CI -0.69 to +0.16. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.26 (p 0.289, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.38 (p 0.123, n 18). could be the mix.
skeptic: leave-one-out range -0.44 to -0.22, sign flips 0; without severely affected donors -0.33 (p 0.182, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TCP11L2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts